Advancing research addressing unmet medical needs in retinal vascular disorders and diabetic eye disease

unmet medical needs

At Oxurion we are dedicated to finding and developing drugs to meet medical needs in ophthalmology. According to the World Health Organization, chronic eye disorders account for more than 80% of visual impairment cases worldwide, with the majority of them being back of the eye diseases.

“Chronic visual disorders have a large impact on people's life. Not being able to drive a car or go to work makes them lose their independence.”
jeff todd | ceo & President | Prevent Blindness
Join us at the ICCI 2022 Conference in Amsterdam    More info

Working at Oxurion.

Text to invite candidates to search jobs or apply for positions.

123 Anthenaeum St.
Cambridge, MA 01234

Gaston Geenslaan 1
B-3001 Leuven

Get In Touch

Diabetic Macular Edema and its treatment challenges.

People who suffer from DME have leaking vessels in the back of the eye. This leakage leads to a thickening of the retina and causes vision problems. Close to 40% of patients don’t respond optimally to current treatments. Moreover, the treatment burden of current therapies is high: patients have to have injections on a monthly basis. Oxurion strives to develop therapies that can serve as an alternative for patients who don’t respond well to current treatments and to lower the burden of treatment.

April 11,2022

Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 ARVO Annual Meeting

May 3, 2022
Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Denver, Colorado, United States
April 2021
Annual Report 2021 (pdf version)

Oxurion’s deep scientific knowledge of diseases affecting the back of the eye has led to the development of a diverse portfolio of disease-modifying therapies aimed to preserve these patients’ vision. Oxurion’s current pipeline is focused on new treatment approaches to diabetic eye disease and macular degeneration.

We Focus on non-VEGF Pathways

Our focus on non-VEGF pathways means first and foremost leaving the anti-VEGF pathway. An anti-VEGF is a good product but it only works for 60% of those with DME, meaning there is no effective treatment for the other 40%. Exploring non-VEGF pathways might provide a chance to better address the current unmet medical need of those 40% DME patients.

Unique Research Pipeline Beyond VEGF

research pre-clinical Phase I Phase II Phase III GO
THR-149 (PKal inhibitor)
THR-687 (Pan RGD integrin antagonist)
Diabetic Retinopathy

Symptomatic VMA/VMT

sVMA/VMT is caused when the vitreous adheres to the macula at the back of the eye in an abnormally strong manner. Because the macula provides central vision for everyday tasks like driving, reading and recognizing faces, the traction that results from this abnormally strong adherence, can cause symptoms like distorted or decreased vision. When it progresses, the traction may lead to formation of a hole in the macula (called a macular hole). For many years the only treatment option for patients with sVMA/VMT was surgical separation of the vitreous from the retina, a procedure called a vitrectomy.

This involves several risks and can lead to complications like bleeding, pain, post-operative inflammation and irritation, so the surgery is only performed after the patient’s vision has deteriorated significantly. Jetrea® is the first and only non-surgical and pharmacological vitreolysis drug approved for the treatment of sVMA/VMT. In March 2020, Oxurion and Inceptua Group signed a global commercial license agreement for Jetrea®.

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

Purpose: The purpose of this study was to evaluate the safety and preliminary efficacy of a single intravitreal injection of 3 dose levels of THR-149 in adults with center-involved diabetic macular edema (DME).

Media Contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team.

Gaston Geenslaan 1
B-3001 Heverlee
Tel: +32 (0) 16 75 13 10

“Exploring non-VEGF pathways might provide a chance to better address the current unmet medical need of 40% of DME patients.”

[   oxurion science leadership team   ]

Let's Talk

Ramin Tadayoni, MD, PHD

Lariboisere University Hospital

Ramin Tadayoni, MD, PHD

Lariboisere University Hospital

Dr. Ramin Tadayoni is Professor of Ophthalmology at University of Paris and Head of the Department of Ophthalmology at Lariboisière University Hospital (Paris, France). He has authored more than 140 medical and scientific articles and has made numerous contributions to ophthalmology textbooks. Dr. Tadayoni completed undergraduate training in medicine at the University of Marseille, and his MD and internship at Paris V University. He completed his studies with a retina fellowship at Lariboisière University Hospital. Simultaneously, he pursued his PhD in science at Paris VII University and the Paris Vision Institute.